1 Stubborn Cloud and 2 Silver Linings for Eli Lilly Stock [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Over the past 30 days, its shares fell by about 10%, though they are still up by around 37% so far this year. And, if management is correct, one cloudy trend driving their recent decrease in performance is more likely to stick around than shareholders would prefer. Nonetheless, things aren't anywhere near as bad as they might seem at the moment. And Eli Lilly's cloud also has a pair of silver linings that investors will want to hear about. Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. Sign Up For Free » Lilly's newest cash cow, tirzepatide -- a therapy for type 2 diabetes and weight loss that's sold under the names Mounjaro and Zepbound -- is selling a bit slower than anticipated. Though its total revenue in the U.S. in the third quarter was $7.8 billion, up 46% from a year prior, $1.2 billion of which was derived from sales of Zepbound (the weight loss brand), the market's expectations were even higher. The reason for the disconnect
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks [Yahoo! Finance]Yahoo! Finance
- Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeksPR Newswire
- Hims & Hers launches GLP-1 shortage tracker in its battle with the FDA [Yahoo! Finance]Yahoo! Finance
- Hims & Hers launches GLP-1 shortage tracker in its battle with the FDA [Yahoo! Finance Canada]Yahoo! Finance Canada
- Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Therapeutics’ Founders to Company’s Scientific Advisory BoardBusiness Wire
LLY
Earnings
- 10/30/24 - Miss
LLY
Sec Filings
- 11/8/24 - Form 144
- 11/8/24 - Form 4
- 11/5/24 - Form 4
- LLY's page on the SEC website